Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HY9S
|
|||
| Drug Name |
BOS172722
|
|||
| Synonyms |
SGWLRDAOCLITOM-UHFFFAOYSA-N; SCHEMBL15515080; CHEMBL3924132; BDBM241338; US9409907, 182
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Boston Pharmaceuticals Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H30N8O
|
|||
| Canonical SMILES |
CCOC1=C(C=CC(=C1)C2=NN=CN2C)NC3=NC=C4C=C(N=C(C4=N3)NCC(C)(C)C)C
|
|||
| InChI |
1S/C24H30N8O/c1-7-33-19-11-16(22-31-27-14-32(22)6)8-9-18(19)29-23-25-12-17-10-15(2)28-21(20(17)30-23)26-13-24(3,4)5/h8-12,14H,7,13H2,1-6H3,(H,26,28)(H,25,29,30)
|
|||
| InChIKey |
SGWLRDAOCLITOM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1578245-44-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dual specificity protein kinase TTK (MPS1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cell cycle | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| WikiPathways | Retinoblastoma (RB) in Cancer | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.